A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infections
Intervention: Indinavir sulfate (Drug); Lamivudine (Drug); Zidovudine (Drug)
Phase: N/A
Status: Completed
Sponsored by: Merck
Summary
To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine
(AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan )
plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.
Clinical Details
Official title: A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
Study design: Treatment, Double-Blind, Safety Study
Detailed description:
AZT-experienced patients are randomized to receive MK-639/AZT/3TC or MK-639 alone or AZT/3TC.
Additionally, patients who have received < 6 months of AZT or who are intolerant but received
prior 3TC or who require concomitant rifampin therapy may receive open-label MK-639.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria
Concurrent Medication:
Allowed for all patients:
- Standard prophylaxis for opportunistic infections.
- Continuation of treatment for opportunistic infection.
Allowed for open-label study patients:
- Rifampin.
Patients must have:
- HIV positivity.
- CD4 count <= 50 cells/mm3.
- More than 6 months of prior AZT (blinded study only).
NOTE:
- Patients on the open-label study must have AZT intolerance or have < 6 months of prior
AZT.
Prior Medication:
Required for blinded study patients:
- > 6 months of prior AZT.
Required for open-label study patients:
- < 6 months of prior AZT.
Allowed for open-label study patients:
- Prior 3TC.
Exclusion Criteria
Concurrent Medication:
Excluded in all patients:
- Immunosuppressants.
Excluded in blinded study patients:
- AZT, ddI, ddC, or d4T.
- Rifampin.
Excluded in open-label study patients:
- 3TC.
Prior Medication:
Excluded in all patients:
- Prior protease inhibitors.
- Investigational agents and immunomodulators within 30 days prior to study entry.
- Immunosuppressants within 2 weeks prior to study entry.
Excluded in blinded study patients:
- Any prior 3TC.
- AZT, ddI, ddC, or d4T within 2 weeks prior to study entry.
Excluded in open-label study patients:
3TC within 30 days prior to study entry.
Locations and Contacts
Merck & Co Inc, Whitehouse Station, New Jersey 088890100, United States
Additional Information
Related publications: Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997 Sep 11;337(11):734-9. Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. J Infect Dis. 1999 Sep;180(3):659-65.
Last updated: June 23, 2005
|
